Krystal Biotech price target raised to $338 from $288 at Clear Street

Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $338 from $288 and keeps a Buy rating on the shares. The shares have moved higher on Vyjuvek growth and building appreciation of its pipeline opportunities, the analyst tells investors in a research note. The firm says “most consistent excitement among investors” is being placed on Krystal’s potential in the neurotrophic keratitis market with KB801. Clear cites increased estimates for KB801 for the target bump.